Insulin Action growing evidence that they have a role in growth factor signalling and perhaps also in endocytosis and in regulating vesicle traffic from the transGolgi network. Defining their true cellular roles will require establishing the nature of their lipid products in vivo and clearly identifying their binding partners in vivo and the mechanisms regulating these interactions. 
Introduction phosphatidylinositol-dependent protein kinase; PI-3K, phosphoinosiide 3-kinase; PKB, protein kinase B; PP, protein phosphatase; SH2, Src homology 2. 'To whom COmsDondence should be addressed (e-mail ~l~~~~~~ is the major energy Store in both liver and muscle: the glycogen in liver is a glucose reservoir for the whole body (including muscle), s.j.yeaman@ncl.ac.uk).
whereas that in muscle serves as a store for muscle only. Both glycogen synthesis and breakdown are under acute hormonal control, with the key enzymes, glycogen synthase (GS) and glycogen phosphorylase respectively, being subject to both allosteric control and reversible phosphorylation.
GS is inactivated by phosphorylation, catalysed at a number of serine residues by a number of protein kinases, whereas glycogen phosphorylase is activated by this modification, which occurs at a single serine residue catalysed by phosphorylase kinase [ 13. Although the control of glycogen breakdown is relatively well understood, much remains to be learnt about the control of glycogen synthesis.
Hormonal control of glycogen synthesis
T h e storage of glucose as glycogen is an essential feature of muscle cell metabolism, with glycogen representing the major energy store for utilization during muscle contraction. Glycogen synthesis is under acute hormonal control, via catecholamines and insulin. A classical action of insulin is the stimulation of glycogen synthesis. At least two steps are involved, first the movement of the insulin-responsive glucose transporter, G L U T 4 , to the plasma membrane of cells, resulting in increased glucose uptake [2] , and secondly the dephosphorylation and activation of GS, leading to increased glycogen synthesis [l] . There is a body of evidence to suggest that both processes are impaired in skeletal muscle and other peripheral tissues of subjects with type 2 diabetes [3] .
A consensus is emerging for the mechanism by which insulin stimulates glycogen synthesis. Binding of insulin to its receptor activates the intrinsic tyrosine kinase activity of the receptor, leading to the phosphorylation of several insulin receptor substrates. These serve as docking modules for several Src homology 2 (SH2)-domaincontaining proteins including phosphoinositide 3-kinase (PI-3K), which is activated as a result of this binding. This enzyme forms PtdIns(3,4,S)P3, which can be considered a second messenger for insulin. T h e formation of PtdIns(3,4,S)P3 stimulates the phosphorylation and activation of protein kinase B (PKB) by a phosphatidylinositoldependent protein kinase PDK-1 (reviewed in [4] ). PKB has a number of substrates, one being glycogen synthase kinase 3 (GSK3), which is phosphorylated at a single serine residue, resulting in its inactivation [S] . T h e inhibition of GSK3 alters the balance between that enzyme and protein phosphatase 1 (PPl), leading to the dephosphorylation of GS at the major regulatory sites and 0 200 I Biochemical Society to the subsequent activation of GS. Inhibition of GSK3 directly, either by the use of selective inhibitors, shown only in liver cells so far [6] , or by Li+ ions [7] , also leads to increased rates of glycogen synthesis, further substantiating the importance of that enzyme. As PKB has also been implicated in the stimulation of glucose uptake by insulin [8] (although there is no evidence for the involvement of GSK3), a concerted mechanism for stimulation of glucose uptake and its subsequent storage as glycogen might exist, allowing glucose uptake to be linked to its storage as glycogen.
However, additional signalling mechanisms are also likely to contribute to the control of glycogen synthesis. For example, we and others have provided evidence for a contribution by a rapamycin-sensitive signalling pathway to the control of glycogen synthesis, presumably involving the p70aQ enzyme system [9, 10] . With the use of human muscle cells we have demonstrated that although rapamycin is without effect on the inactivation of GSK3 in response to insulin and to epidermal growth factor [ l l ] , it partly blocks the activation of glycogen synthesis and GS by these ligands, suggesting that a rapamycin-sensitive pathway influences glycogen synthesis independently of GSK3. There is also evidence that GS becomes dephosphorylated at sites other than those that are acted upon by GSK3, providing further evidence for the involvement of additional kinases (and phosphatases) [12] . It also seems that at least one other kinase might act on sites 3, in that when the priming site (site 5) is mutated to alanine, thus rendering sites 3 and 4 inaccessible to GSK3, phosphorylation of sites 3 still occurs [13] . Further evidence for an additional pathway comes from recent work from this laboratory demonstrating that when GSK3 is maximally inhibited by Li+ ions, resulting in increased glycogen synthesis, the addition of insulin causes a further increase in the rate of glycogen synthesis, which can be blocked by the addition of rapamycin [7] . Therefore, although it seems clear that a principal factor in the control of GS by insulin is the dephosphorylation of sites 3 resulting from a decrease in the activity of GSK3, the role of other contributions to the dephosphorylation of sites 3, and indeed sites 2 and 2a, has yet to be fully established.
Effects of amino acids on glycogen synthesis
In view of a possible role of a rapamycin-sensitive pathway in the stimulation of glycogen synthesis, we have studied the effects of amino acids on glycogen synthesis in human myoblasts, as several groups have reported that after amino acid deprivation the readdition of amino acids stimulates the p70'" pathway. By using these cells we have demonstrated that physiological concentrations of amino acids can directly stimulate glycogen synthesis in the absence of insulin, the magnitude of the effect being similar to that seen in response to insulin [7] . Details of the mechanism responsible are incomplete but it involves the transient inhibition of GSKS without the activation of PKB and is sensitive to inhibition by wortmannin and rapamycin, implicating the mTOR (mammalian target of rapamycin)/p7OS " signalling pathway in the process. Also, because amino acids (unlike insulin) stimulate this pathway without effects on the MAP kinase/p908 6k pathway or on the activity of PKB, this provides further evidence that the p70'" pathway can directly control glycogen synthesis in the absence of another signal input. T h e transient nature of the inhibition of GSK3 (maximal after 15 min) does not coincide with the prolonged activation of GS and p70s6k, which persists for up to 2 h. It is therefore possible that transient inactivation of GSKS triggers the activation of GS, which could then be maintained by a further rapamycin-sensitive pathway, perhaps acting on G S without an involvement of GSK3.
T h e amino-acid-stimulated activation of p7OSm observed in the human muscle cell lines is sensitive to wortmannin and to rapamycin. Rapamycin acts by associating with a cellular protein FKBPl2 (FK506 binding protein) ; this complex then binds to mTOR, inhibiting its kinase activity. This would therefore indicate that mTOR is required for the response to amino acids, either directly or through the regulation of a downstream element such as p7OSfik or a protein phosphatase. Although mTOR has been shown to phosphorylate p7OESk directly in vitro [14] , recent evidence points also to a role for the activation of PP2A, which is activated by rapamycin, via the inhibition of mTOR [15]. PI-3K is also implicated because of the wortmannin sensitivity; however, it has previously been reported that wortmannin can selectively inhibit mTOR directly by binding to the catalytic domain at concentrations of 0.1-1 pM [16, 17] . It is therefore possible that PI-3K does not have a role in this mechanism despite the wortmannin-sensitive nature of the process. It has also been reported that PDK-1 can phosphorylate p708 6k in oivo [ 171 but there is as yet no evidence to suggest that PDK-1 kinase activity is increased in response to amino acids, especially as PKB activity does not increase under these conditions.
The sustained amino-acid-stimulated activation of p7OSfik and its sensitivity to both wortmannin and rapamycin leads to the reasoning that this enzyme is part of the signal mechanism involved in the amino-acid-stimulated increase in GS and glycogen synthesis activities. Although a very obvious explanation would be that p70'" phosphorylates GSK3 directly and causes its transient inactivation, it is important to point out that other mechanisms are possible and that ~7 0 "~ itself might not have a role. It is plausible that events might stem directly from mTOR. It has recently been discovered that mTOR can cause the activation of PP2A [lS], which is known to act on GSK3 in vitro. This could provide evidence to support a theory in which GSK3 is regulated by this phosphatase in response to the availability of amino acids. PP2A also has the ability to dephosphorylate GS at sites 2 and 3, leading to its activation; this phosphatase might therefore have a co-ordinating role in the overall process. Clearly an analysis of the sites on GS that become dephosphorylated in response to amino acids will lead to an increased understanding of the processes involved.
In our study, a complete mixture of amino acids was used to stimulate glycogen synthesis ; however, other studies with rat L6 myotubes have shown effects of the mTOR pathway in response to the addition of L-leucine alone [18]. Additional studies in a variety of experimental systems have reported that leucine is the most potent stimulator of the mTOR/p7086k pathway but that the presence of additional amino acids increases the stimulation by leucine [19] . Clearly it will be important to examine the molecular mechanism underlying these effects, to determine which amino acids are responsible, to determine whether the amino acids themselves exert the effects intracellularly, and to clarify whether these effects are of physiological significance and, if so, under what conditions.
Effects of glucose and glycogen on glycogen synthesis
Glycogen synthesis is also stimulated under certain conditions in an insulin-independent manner. One prime example is the period after exercise, for which both an insulin-dependent and an insulinindependent mechanism for the stimulation of glycogen synthesis have been described [20] . Exercise is associated with extensive glycogen depletion [21] ; this has led us to investigate effects of glycogen levels on the subsequent rates of glycogen synthesis. Again with the use of human muscle cells in culture, we have demonstrated that the rate of glycogen synthesis is stimulated markedly by glucose after glycogen depletion resulting from glucose deprivation, which is akin to the situation after strenuous exercise when glycogen stores are severely depleted as a result of the exercise. After glycogen depletion, glucose markedly stimulates glycogen synthesis and increases the activity state of GS, without observable effects on the activity of GSK3 or PP1 [22]. T h e mechanism for this remains to be explained but might involve an effect of glucose 6-phosphate making GS a better substrate for dephosphorylation by  PP1 [23] . Alternatively, the loss of glycogen might cause alterations in the distribution of the key enzymes within the cell, perhaps favouring the interaction between GS and protein phosphatases at the expense of interactions of GSK3 and/or other kinases that regulate GS. Clearly, a determination of the sites on GS that are dephosphorylated in response to glucose would shed light on the molecular events involved.
Interestingly, whereas glucose uptake is increased both during and after exercise, a process that seems to involve the AMP-activated protein kinase [24], glycogen synthesis is inhibited during exercise (thus favouring glycolysis and A T P production) ; however, glycogen synthesis is stimulated after the cessation of exercise, leading to a replenishment of the glycogen stores. It is known that GS is a substrate for the AMP-activated protein kinase, at least in vitro, and it is possible that this kinase is responsible for the decrease in the activity ratio of GS observed during glycogen depletion. In this regard it is of interest that both the a and isoforms of AMP-activated protein kinase are activated in the human myoblasts during glucose deprivation but then return rapidly to basal levels upon glucose readministration (R. Halse, L. Fryer, D. Carling and S. Yeaman, unpublished work), but as yet there is no evidence that the AMP-activated kinase acts directly on GS under these (or any other) conditions. Again, analysis of the phosphorylation sites on GS that are involved will further our understanding of the response. Certainly the possibility is attractive that the AMP-activated kinase both stimulates glucose uptake during exercise and limits its conversion into glycogen until the exercise has ceased. However, the switch that releases the inhibition of GS at the cessation of exercise has yet to be determined.
Conclusion
At least three signalling pathways contribute to the control of glycogen synthesis in muscle (Scheme 1). These pathways are triggered by hormones such as insulin and adrenaline but also by nutritional factors such as amino acids and glucose. In addition, intracellular conditions such as the glycogen content of the cells can significantly influence the degree of stimulation of these pathways. Clearly, further knowledge of the interaction between the different inputs will be necessary to gain a full understanding of the control of glycogen synthesis under various metabolic conditions. Work in our laboratory was supported by Diabetes UK, BBSRC, Novo Nordisk, Glaxo SmithKline and Xcellsyz.
ation of eukaryotic initiation factors and elongation factors (eIFs and eEFs respectively) and of other regulatory proteins. This modulates their activities or their abilities to interact with one another. Insulin activates several of these proteins including the following : the guanine-nucleotide exchange factor eIF2B ; the eIF4F complex, which (through eIF4E) interacts with the cap of the mRNA; p70 S6 kinase; and elongation factor eEF2, which mediates the translocation step of elongation. Control of the last three of these is linked to mTOR (mammalian target of rapamycin). In Chinese hamster ovary cells, regulation
